# The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

> **NCT06030843** · PHASE2,PHASE3 · RECRUITING · sponsor: **Chulalongkorn University** · enrollment: 200 (estimated)

## Conditions studied

- Empagliflozin in Cardiorenal Syndrome Type 1

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06030843
- **Lead sponsor:** Chulalongkorn University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06030843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06030843, "The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06030843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*